title: Strategy for the treatment of multiple myeloma utilizing monoclonal antibodies: A new era begins.
abstract: Novel agents, such as immunomodulantory drugs (IMiDs) and proteasome inhibitors (PI), have significantly improved overall survival of multiple myeloma (MM) patients. Yet, MM remains an incurable disease, relapse inevitably occurs and patients tend to become resistant to subsequent treatments. This led to the evaluation of new treatment strategies. The recent development of monoclonal antibodies is changing the treatment algorithm of MM by increasing the therapeutic armamentarium. Elotuzumab and Daratumumab were shown to be very effective and are likely to be soon approved by the FDA. Other antibodies are in pre-clinical or early clinical phases of evaluation and further investigation and more robust data are needed. This review will give an overview of the most active monoclonal antibodies against MM.
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Magarotto
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Salvini
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Francesca
authors.initials: F
authors.lastname: Bonello
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Bringhen
authors.affiliation: a Myeloma Unit, Division of Hematology , University of Torino , Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino , Torino , Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002448:Cell Adhesion / Q000187:drug effects; D002986:Clinical Trials as Topic; D003165:Complement System Proteins / Q000276:immunology; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects; D058990:Molecular Targeted Therapy; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D019139:Tumor Escape / Q000187:drug effects / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D003165:Complement System Proteins
keywords: Daratumumab; SAR650984; elotuzumab; monoclonal antibodies; multiple myeloma; novel agents; siltuximab